Our mission is to digitize, decode, and decipher human biology for the prevention, early diagnosis, and treatment of chronic diseases and cancer.
The Central Dogma Of Molecular Biology Is No Longer Simply Defined By The Static Nature Of DNA.
Microbial and human gene expression are now redefining how biological activities are viewed in relation to human health. The coupling of Viome's metatranscriptomic and machine learning platform are revolutionizing the potential of precision therapeutics. Historically, traditional exploration of disease states have failed to include the significant impact of gut microbial populations on systemic inflammation and disease development. Offering health insights accumulated from hundreds of thousands of samples, Viome's platform digitizes biological information and analyzes it to identify novel therapeutic targets.
Our Unique Approach
We use a systems biology approach to deeply understand the origin and progression of disease using gene expression (mRNA) analysis with a state-of-the-art AI platform.
DNA
Rarely changes
Similar sequence in every organ & cell
Explains 5–10% of chronic diseases *
mRNA
Dynamic, constantly changing
Vastly different expression in the body
Explains 80% of chronic diseases
What is mRNA?
Messenger RNA, or mRNA, plays a fundamental role in human biology, transferring the instructions stored in DNA to make the proteins required in every living cell. Our approach is to use mRNA medicines to instruct a patient's own cells to produce proteins that could prevent, treat, or cure disease.
Tapping into Holistic Systems Biology
Viome sample analysis today
- Stool metatranscriptomics (CLIA, Production)
- Whole blood metatranscriptomics (CLIA, Production)
- Saliva metatranscriptomics
Our technology is being used to digitize the human body through the collection of a variety available specimen types.
Viome utilizes the current meta-dataset of sequenced samples as a starting point for the investigation into various disease therapeutics.
Future
- Throat metatranscriptomics
- Vaginal metatranscriptomics
- Cerebrospinal fluid metatranscriptomics & metagenomics
- Nasopharyngeal metatranscriptomics
- Synovial fluid metatranscriptomics & metagenomics
- Urine metatranscriptomics
- Plasma metatranscriptomics & metagenomics (normal collection & differential centrifugation)
Viome's
mRNA Platform
Increasing every day, Viome boasts access to an mRNA platform of more than a quarter million samples to generate and test hypotheses related to many chronic diseases and cancers. At our core, Viome focuses on establishing biological data trends that identify the patterns for optimal health. Our initiative integrates a robust dataset with innovative technology to determine causal relationships that evaluate and improve the current understanding of chronic diseases as we know them.
Metatranscriptomic
Technology
Viome metatranscriptomic technology is only clinically validated metatranscriptomic technology in the world.
Insight to Intervention
PREVENTION
Our direct-to-consumer service analyzes gene expressions (mRNA) in order to provide individuals with health insights and precision nutrition to live a healthier life.
This platform of over 300,000 samples enables us to enhance our understanding of human biology as a system in order to develop predictive biomarkers, precision diagnostics, and precision therapeutics to prevent and intercept chronic diseases.
Clinical improvements in IBS, Diabetes, Depression & Anxiety.
DIAGNOSIS
Our predictive biomarkers provide us with the hypothesis to do clinical research and identify the signatures of chronic diseases, cancers, and aging.
Successfully developed over 30 predictive models for Glycemic response, Obesity, Diabetes, Depression, IBS, and Oral Cancer, which represent over 50% of chronic diseases.
FDA Breakthrough Device Designation for oral & throat cancer to detect early-stage throat cancer and oral cancer with 95% specificity and 90% plus sensitivity.
THERAPEUTICS
The signatures found through diagnostics allow us to determine the mechanism of action to develop precision therapeutics in the form of drugs and vaccines.
Viome can determine drug effectiveness, including immunotherapy, which is dependent upon the gut microbiome.
Contracts with large pharma company to develop vaccines for colorectal cancer and an autoimmune disease.
Viome transforms samples into effective Dx and Tx
The ViOS Platform
Our ViOS platform, which includes advanced AI and System Biology, is applied to a proprietary dataset of 325,000 human samples and metadata with the objective to better understand pathogenic processes. With the ViOS platform, the precise characterization of human gene expression and human-microbial interactions enables the delivery of new diagnostics and treatments against chronic diseases.
Viome has converted human biology into a big data problem
500 trillion RNA base pairs sequenced to date
Stool Microbiome
Blood Transcriptome
Saliva Microbiome
Viome Molecular Services (VMS) Architecture
Viome diagnostics:
FDA Breakthrough Device Designation for mRNA Cancer Detect™
Viome Health Sciences R&D efforts focused on diseases with high unmet need
Utilizing Human Gene Expression And Microbial To Identify New Biomarkers For Targeted Therapeutics
Integration of new data insights accumulated from our consumer platform are readily evolving and expanding the current understanding of chronic disease prevention, prediction, diagnostics, prognostics, and therapeutics.
Our Partners
Collaborations for therapeutics and opportunities to improve speed, cost and risk for partners
Signed and in-process partnerships
Partnership opportunities
- Novel target identification
- Better understanding of root causes of chronic disease
- Unparalleled insight into healthy vs diseased individuals
- Analyzing metatranscriptome provides insight into how body is responding to treatment
- Prognostic and biomarker capabilities: excluding non-responders for higher success rates
- Virtual trial enrollment
- Faster patient enrollment